HEALTHSTAT NEWS
STAT+: Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study
Eli Lilly reported a 62% reduction in LDL cholesterol levels in a Phase 1 trial using its gene-editing therapy, VERV-102, acquired from Verve Therapeutics. The therapy showed no serious adverse events, marking a significant safety improvement over Verve's previous shelved candidate. The treatment is positioned as a potential one-time solution for preventing heart disease.
Mentioned
Related Signal
Adjacent reporting
- Clinical trial shows gene editing works for β-Thalassaemia, too
- New treatment cuts bad cholesterol by nearly 50% without statins
- First human GLP-1 gene therapy trial gets green light
- I was stunned when a blood test showed how high my cholesterol levels were. Then I turned to something you can buy in any supermarket - and it fixed me overnight without any of the side effects of statins
- I was stunned when a blood test showed how high my cholesterol levels were. Then I turned to something you can buy in any supermarket - and it fixed me overnight without any of the side effects of statins
- Genome editing can be risky. Meet the epigenome editors